Company news

Compass Therapeutics, Inc. news in 2025

Compass Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

December 16, 2025

Compass Therapeutics to Participate in Upcoming December Investor Events

November 24, 2025

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 4, 2025

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 3, 2025

Compass Therapeutics to Participate in Upcoming November Investor Events

November 2, 2025

Compass Therapeutics to Participate in Upcoming September Investor Events

August 25, 2025

Compass Therapeutics Announces Proposed Public Offering

August 11, 2025

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

August 11, 2025

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

August 10, 2025

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

August 7, 2025

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 27, 2025

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

May 7, 2025

Compass Therapeutics to Participate in Upcoming May Investor Events

May 5, 2025

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

April 27, 2025

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

April 20, 2025

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

April 1, 2025

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

March 31, 2025

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

March 30, 2025

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

February 26, 2025

Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

January 28, 2025

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

January 7, 2025

Calls in 2025

Decks in 2025